ArticleClinical cancer research : an official journal of the American Association for Cancer Research2017
PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses.
Erratum issuedAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 76 papers.
0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 172 citations in OpenAlex.
- Very low-carbohydrate ketogenic diet in treatment-naïve women with endometrial cancer and overweight: a randomized feasibility study.Nature communications · 2026Trial
- The dysregulation of the immune microenvironment during endometrial intraepithelial neoplasia serves as a marker of endometrial carcinogenesis.Frontiers in immunology · 2026Review
- Family with sequence similarity 114 member A1 orchestrates immune evasion in triple-negative breast cancer.Signal transduction and targeted therapy · 2025Article
- Targeting the Phosphoinositide 3-Kinase/Protein Kinase B Pathway Suppresses Y-Box Binding Protein 1 Expression and Inhibits Colorectal Cancer Progression.World journal of oncology · 2025Article
- CARM1-Mediated MAP2K4 Methylation Potentiates the Oncogenic Functions of MAP2K4 and Constitutes a Targetable Dependency in Triple-Negative Breast Cancer.Cancer research · 2025Article
- Predicting immune responsiveness in ER-positive breast cancer for personalized therapy: a population-based study.NPJ precision oncology · 2025Article
- Oncogenic Signalling Pathways in Cancer Immunotherapy: Leader or Follower in This Delicate Dance?International journal of molecular sciences · 2025Review
- Propionyl-CoA carboxylase subunit B regulates anti-tumor T cells in a pancreatic cancer mouse model.eLife · 2025Article
- Targeting PI3K Signaling to Overcome Tumor Immunosuppression: Synergistic Strategies to Enhance Cancer Vaccine Efficacy.Vaccines · 2025Review
- Indole-3-carbinol prevented tumor progression and potentiated PD1ab therapy by upregulating PTEN in colorectal cancer.Discover oncology · 2025Article
- Roles and functions of tumor-infiltrating lymphocytes and tertiary lymphoid structures in gastric cancer progression.Frontiers in immunology · 2025Review
- Targeting PI3Kδ in cancer: a setback or the end.Frontiers in oncology · 2025Article
- Immune evasion and resistance in breast cancer.American journal of cancer research · 2025Review
- Alpelisib and Immunotherapy: A Promising Combination for Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.Cancer reports (Hoboken, N.J.) · 2024Article
- Towards targeting the breast cancer immune microenvironment.Nature reviews. Cancer · 2024Review
- Beyond Anti-PD-1/PD-L1: Improving Immune Checkpoint Inhibitor Responses in Triple-Negative Breast Cancer.Cancers · 2024Review
- Targeting MEK/COX-2 axis improve immunotherapy efficacy in dMMR colorectal cancer with PIK3CA overexpression.Cellular oncology (Dordrecht, Netherlands) · 2024Article
- PI3K/mTOR inhibition induces tumour microenvironment remodelling and sensitises pS6Clinical and translational medicine · 2024Article
- Endogenous pAKT activity is associated with response to AKT inhibition alone and in combination with immune checkpoint inhibition in murine models of TNBC.Cancer letters · 2024Article
- A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation.Molecular cancer · 2024Article
16 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
17 authors at 1 institution in 1 country.
Jiqing SaiTennessee Valley Healthcare System, Department of Veterans Affairs, Nashville, Tennessee.
Philip OwensTennessee Valley Healthcare System, Department of Veterans Affairs, Nashville, Tennessee.
Sergey V NovitskiyDepartment of Medicine, Vanderbilt University, Nashville, Tennessee.
Oriana E HawkinsTennessee Valley Healthcare System, Department of Veterans Affairs, Nashville, Tennessee.
Anna E VilgelmTennessee Valley Healthcare System, Department of Veterans Affairs, Nashville, Tennessee.
Jinming YangTennessee Valley Healthcare System, Department of Veterans Affairs, Nashville, Tennessee.
Tammy SobolikTennessee Valley Healthcare System, Department of Veterans Affairs, Nashville, Tennessee.
Nicole LavenderTennessee Valley Healthcare System, Department of Veterans Affairs, Nashville, Tennessee.
Andrew C JohnsonTennessee Valley Healthcare System, Department of Veterans Affairs, Nashville, Tennessee.
Colt McClainDepartment of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, Tennessee.
Gregory D AyersDepartment of Biostatistics, Vanderbilt University, Nashville, Tennessee.
Mark C KelleyDepartment of Surgical Oncology, Vanderbilt University, Nashville, Tennessee.
Melinda SandersDepartment of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, Tennessee.
Ingrid A MayerDepartment of Medicine, Vanderbilt University, Nashville, Tennessee.
Harold L MosesDepartment of Cancer Biology, Vanderbilt University, Nashville, Tennessee.
Mark BoothbyDepartment of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, Tennessee.
Ann RichmondTennessee Valley Healthcare System, Department of Veterans Affairs, Nashville, Tennessee. ann.richmond@vanderbilt.edu.
Vanderbilt University · US
Funding
Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI STACIE B DUSETZINA · 1995 to 2026
$172.8MThe Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4MVanderbilt Clinical Oncology Research Career Development ProgramK12CA090625 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Debra L. Friedman, Paula Jill Hurley · 2001 to 2026
$16.9MIntegrated Biological Systems Training in OncologyT32CA119925 · NCI · VANDERBILT UNIVERSITY · PI Vivian Gama, William Patrick Tansey · 2008 to 2026
$7.6MMELANOMA GROWTH STIMULATORY ACTIVITYR01CA034590 · NCI · VANDERBILT UNIVERSITY · PI RICHMOND, ANN · 1986 to 2017
$5.2MRoles of rictor in mTOR signaling, differentiation & immune memory via Akt & PKCR01HL106812 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BOOTHBY, MARK R · 2011 to 2018
$3.1MRole of Adenosine in TGF-beta Effects in CancersR01CA200681 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI NOVITSKIY, SERGEY V. · 2016 to 2020
$1.8MChemokine Receptor Modulation of the Tumor MicroenvironmentF32CA171895 · NCI · VANDERBILT UNIVERSITY · PI HAWKINS, ORIANA E. · 2012 to 2012
$46kTargeting the BMP pathway in metastatic cancerIK2BX002929 · VA · VETERANS HEALTH ADMINISTRATION · PI OWENS, PHILIP · 2016 to 2021
–Modeling New Therapeutic Approaches for Malignant MelanomaI01BX002301 · VA · VETERANS HEALTH ADMINISTRATION · PI Julie A Rhoades (Sterling) · 2014 to 2026
–BLRD VA I01 BX002301BLRD VA IK2 BX002929BLRD VA IK6 BX005225NCATS NIH HHS UL1 TR000445NCI NIH HHS F32 CA171895NCI NIH HHS K12 CA090625NCI NIH HHS P30 CA068485NCI NIH HHS R01 CA034590NCI NIH HHS R01 CA200681NCI NIH HHS T32 CA119925NHLBI NIH HHS R01 HL106812
Abstract
PubMed holds no abstract for this paper.
Indexed as
AminopyridinesAnimalsCell Line, TumorCell ProliferationClass Ib Phosphatidylinositol 3-KinaseFemaleHumansImmunity, CellularMammary Neoplasms, AnimalMiceMorpholinesNeoplasm MetastasisPhosphoinositide-3 Kinase InhibitorsProgrammed Cell Death 1 ReceptorProtein Kinase InhibitorsSignal TransductionAminopyridinesClass Ib Phosphatidylinositol 3-KinaseMorpholinesNVP-BKM120Pdcd1 protein, mousePhosphoinositide-3 Kinase InhibitorsPik3cg protein, mouseProgrammed Cell Death 1 ReceptorProtein Kinase Inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.